Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation

American Journal of Gastroenterology

Volumn 105, Issue 8, 2010, Pages 1789-1794

  Keohane, John ^a   O'Mahony, Caitlin ^a   O'Mahony, Liam ^a   O'Mahony, Siobhan ^a   Quigley, Eamonn M ^a   Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; FECES; FECES LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INFLAMMATION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; ULCERATIVE COLITIS;

EID: 77955419649     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.156     Document Type: Article

References (42)

1. Simren M, Axelsson J, Gillberg R et al. Quality of life in inflammatorybowel disease in remission: the impact of IBS-like symptoms and associatedpsychological factors. Am J Gastroenterol 2002; 97: 389-396
2. Minderhoud IM, Oldenburg B, Wismeijer JA et al. IBS-like symptoms inpatients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-474
3. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling theepidemiology of inflammatory bowel diseases. Gut 2008; 57: 1185-1191
4. Hungin AP, Whorwell PJ, Tack J et al. The prevalence, patterns and impactof irritable bowel syndrome: an international survey of 40 000 subjects.Aliment Pharmacol Ther 2003; 17: 643-650
5. Hungin AP, Chang L, Locke GR et al. Irritable bowel syndrome in theUnited States: prevalence, symptom patterns and impact. Aliment PharmacolTher 2005; 21: 1365-1375
6. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatorybowel disease in the United States: results from the National Health InterviewSurvey. Am J Gastroenterol 2003; 98: 1064-1072 (Pubitemid 36733768)
7. Rogala L, Miller N, GraffLA et al. Population-based controlled study of socialsupport, self-perceived stress, activity and work issues, and access to health carein inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 526-535
8. Bernstein CN, Kraut A, Blanchard JF et al. The relationship betweeninflammatory bowel disease and socioeconomic variables. Am J Gastroenterol2001; 96: 2117-2125
9. Creed F, Ratcliffe J, Fernandez L et al. Health-related quality of life andhealth care costs in severe, refractory irritable bowel syndrome. Ann InternMed 2001; 134: 860-868
10. Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritablebowel syndrome. Aliment Pharmacol Ther 1997; 11: 1019-1030
11. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's diseaseactivity index. National Cooperative Crohn's Disease Study. Gastroenterology1976; 70: 439-444
12. Walmsley RS, Ayres RC, Pounder RE et al. A simple clinical colitis activityindex. Gut 1998; 43: 29-32.
13. Th ompson WG, Longstreth GF, Drossman DA et al. Functional boweldisorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II43-7.
14. Guyatt G, Mitchell A, Irvine EJ et al. A new measure of health status for clinicaltrials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810 (Pubitemid 19057603)
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. ActaPsychiatr Scand 1983; 67: 361-370 QOL.
16. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinalabnormality. Lancet 2000; 356: 1783-1784
17. Tibble JA, Sigthorsson G, Foster R et al. Use of surrogate markers of inflammationand Rome criteria to distinguish organic from nonorganic intestinaldisease. Gastroenterology 2002; 123: 450-460
18. Tibble J, Teahon K, Th jodleifsson B et al. A simple method for assessingintestinal inflammation in Crohn's disease. Gut 2000; 47: 506-513
19. Tibble JA, Sigthorsson G, Bridger S et al. Surrogate markers of intestinalinflammation are predictive of relapse in patients with inflammatory boweldisease. Gastroenterology 2000; 119: 15-22.
20. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification ofinflammatory bowel disease: controversies, consensus, and implications.Gut 2005; 55: 749-753
21. Irvine EJ. Assessing outcomes in clinical trials. In Satsangi J, Sutherland LR(eds). Inflammatory Bowel Disease. Churchill Livingstone: London, 2003,pp. 319-333
22. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful,magic, or unnecessary toys? Gut 2006; 55: 426-431
23. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers ininflammatory bowel disease. Dis Colon Rectum 2008; 51: 1283-1291
24. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indicesand efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786
25. Dinan TG, Quigley E, O'Mahony S et al. Hypothalamic-pituitary-gut axisdysregulation in irritable bowel syndrome: plasma cytokines as a potentialbiomarker? Gastroenterology 2006; 130: 304-311
26. O'Mahony L, McCarthy J, Kelly P et al. A randomized, placebocontrolled, double-blind comparison of the probiotic bacteria lactobacillusand bifidobacterium in irritable bowel syndrome (IBS): symptom responsesand relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
27. Liebregts T, Adams B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920
28. Macsharry J, O'Mahony L, Fanning A et al. Mucosal cytokine imbalance inirritable bowel syndrome. Scand J Gastroenterol 2008; 27: 1-10.
29. Aerssens J, Camilleri M, Talloen W et al. Alterations in mucosal immunityidentified in the colon of patients with irritable bowel syndrome.Clin Gastroenterol Hepatol 2008; 6: 194-205.
30. Schoepfer AM, Schaffer T, Seibold-Schmid B et al. Antibodies to flagellinindicate reactivity to bacterial antigens in IBS patients. NeurogastroenterolMotil 2008; 20: 1110-1118
31. Shanahan F. Enteric neuropathophysiology and inflammatory boweldisease. Neurogastroenterol Motil 1998; 10: 185-187
32. Mawe GM, Collins SM, Shea-Donohue T. Changes in enteric neural circuitryand smooth muscle in the inflamed and infected gut. NeurogastroenterolMotil 2004; 16 (Suppl 1): 133-136
33. Otten CM, Kok L, Witteman BJ et al. Diagnostic performance of rapidtests for detection of fecal calprotectin and lactoferrin and their ability todiscriminate inflammatory from irritable bowel syndrome. Clin Chem LabMed 2008; 46: 1275-1280
34. Schoepfer AM, Trummler M, Seeholzer P et al. Discriminating IBD fromIBS: comparison of the test performance of fecal markers, blood leukocytes,CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-39
35. Langhorst J, Elsenbruch S, Koelzer J et al. Noninvasive markers in theassessment of intestinal inflammation in inflammatory bowel diseases:performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, andclinical indices. Am J Gastroenterol 2008; 103: 162-169
36. Desmond AN, O'Regan K, Curran C et al. Crohn's disease: factors associatedwith exposure to high levels of diagnostic radiation. Gut 2008; 57: 1524-1529
37. O'Leary C, Wieneke P, Buckley S et al. Celiac disease and irritable boweltypesymptoms. Am J Gastroenterol 2002; 97: 1463-1467
38. O'Leary C, Quigley EMM. Small bowel bacterial overgrowth, coeliac disease,and IBS: what are the associations? Am J Gastroenterol 2003; 98: 720-722
39. Quigley EM. Irritable bowel syndrome and inflammatory bowel disease:interrelated diseases? Chin J Dig Dis 2005; 6: 122-132
40. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the managementof irritable bowel syndrome in North America. Am J Gastroenterol2002; 97 (11 Suppl): S7-26.
41. Quigley EM, Shanahan F. The language of medicine: words as servants andscoundrals. Clin Med 2009; 9: 131-135
42. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy:postinfectious irritable bowel syndrome and inflammatory bowel diseaseirritablebowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 48-53.